Pregabalin is a recently introduced α 2-δ subunit ligand at the voltage- sensitive calcium channel that has shown good efficacy with a tolerable side-effect profile in the treatment of PDN.

Compared with gabapentin, pregabalin was more efficacious and safer for the treatment of neuropathic pain, with significant reductions in pain intensity and duration, opioid use, and adverse events.